TECP
ALT icon

Trails Edge Capital Partners’s Altimmune ALT Stock Holding History

Trails Edge Capital Partners’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.09M Buy
+2,660,000
New +$7.94M 1.28% 28

Other funds holding ALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Trails Edge Capital Partners's ALT Position: Q2 2026 in Review

Trails Edge Capital Partners opened a new position in Altimmune (ALT) in Q2 2026: 2,660,000 shares worth $8.09M. The stake represents 1.28% of the portfolio and ranks #28 among its holdings.

195 funds tracked by Wall St. Rank hold ALT as of Q2 2026.

  • Trails Edge Capital Partners held 2,660,000 shares of Altimmune worth $8.09M as of Q2 2026.
  • Altimmune was a new Trails Edge Capital Partners position in Q2 2026.
  • Altimmune made up 1.28% of Trails Edge Capital Partners's portfolio in Q2 2026, its #28 holding.
  • 195 funds tracked by Wall St. Rank held Altimmune as of Q2 2026.

Based on Trails Edge Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.